bosutinib
Sign in to saveBosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Article
7 sectionsContents
- Mechanism
- Medical uses
- Contraindications
- Interactions
- Notes
- See also
- References
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.
Connections
Categories
4-Methylpiperazin-1-yl compoundsAnilinesCatechol ethersChloroarenesCyanopyridinesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs developed by PfizerDrugs with non-standard legal statusECHA InfoCard ID from WikidataNon-receptor tyrosine kinase inhibitors